Drug monitoring for children with IBD

This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.

This trial uses special fluorescent versions of adalimumab and risankizumab to see inflammation in the bowel during an endoscopic procedure. It may help find out which treatment works best for each person's inflammation.

This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.

This study looks at different ways to measure the amount of biologic drugs in your blood. It is for people with inflammatory bowel disease who are about to start a new biologic therapy or have never taken one before.

This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.

This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.